GenBioPro believes that all people have the right to access high-quality and evidence-based health care, including medical abortion care. To that end, GenBioPro has challenged states' ability to restrict access to medical abortion beyond the FDA's carefully considered requirements, and it defends access to medical abortion when attacked in the courts by extremist groups and Attorneys General.

 

Protecting access from extremist attacks

The Alliance for Hippocratic Medicine and other anti-abortion extremists challenged FDA's approval of the medical abortion regimen in late 2022. In June 2024, the Supreme Court ruled that the Alliance and other plaintiffs did not have standing to seek their requested relief. GenBioPro submitted friend of the court briefs in the case.

When the Attorney Generals of Missouri, Idaho, and Kansas sought to continue the Alliance’s challenge to the medical abortion regimen, GenBioPro sought to intervene as a party to defend it. GenBioPro was granted intervention in April 2025. Subsequently, two similar cases were filed in 2025, one by the Attorney General of Louisiana and another by the Attorneys General of Texas and Florida. Those cases are proceeding and GenBioPro has sought to intervene in Louisiana. GenBioPro will continue to use all available tools to protect access to medical abortion care.

 

Challenging state abortion bans and restrictions

Even before the Supreme Court's Dobbs decision, GenBioPro was working to protect access to medical abortion. In 2019, GenBioPro challenged Mississippi's ability to restrict the use of medical abortion. Because that case was still in its early stages when the Supreme Court issued the Dobbs decision, GenBioPro decided it was more important to challenge one of the new state bans.

In January 2023, GenBioPro challenged West Virginia's ban and restrictions of medical abortion. The federal district court ruled that GenBioPro could bring the case against restrictions but dismissed the challenge to the ban.  Despite support from legal and medical experts as well as communities affected by the ban, the US Court of Appeals for the Fourth Circuit agreed with the district court in 2025.